| 1.0E-6 0 (0%) | 04-24 15:50 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 80.62 | 1-year : | 83.96 |
| Resists | First : | 69.02 | Second : | 71.88 |
| Pivot price | 66.13 |
|||
| Supports | First : | 64.38 | Second : | 53.57 |
| MAs | MA(5) : | 64.83 |
MA(20) : | 66.94 |
| MA(100) : | 70.04 |
MA(250) : | 71.62 |
|
| MACD | MACD : | -1.2 |
Signal : | -1 |
| %K %D | K(14,3) : | 7.4 |
D(3) : | 8.8  |
| RSI | RSI(14): 31.3 |
|||
| 52-week | High : | 83 | Low : | 61.34 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NATH ] has closed above bottom band by 21.3%. Bollinger Bands are 15.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 64.63 - 64.95 | 64.95 - 65.26 |
| Low: | 63.45 - 63.86 | 63.86 - 64.25 |
| Close: | 63.81 - 64.44 | 64.44 - 65.07 |
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.
Wed, 27 Jun 2018
Anthera Pharmaceuticals Announces Withdrawal of its Nasdaq Hearing Request and Suspension of Trading of its ... - GlobeNewswire
Mon, 28 Aug 2017
Anthera Announces Top Line Final Data from the Extension Period of the Phase 2 BRIGHT-SC Study of Blisibimod in ... - GlobeNewswire
Wed, 09 Aug 2017
Anthera Announces FDA Orphan Drug Designation for Blisibimod for the Treatment of IgA Nephropathy - GlobeNewswire
Thu, 22 Jan 2015
Matt Drapkin's Becker Drapkin Management Keeps Trimming Its Stake in This Stock - Insider Monkey
Thu, 16 Jan 2014
Tang Capital Management Discloses Moves into La Jolla Pharmaceutical Company (LJPCD), Vanda Pharmaceuticals ... - Insider Monkey
Fri, 27 Sep 2013
A Promising Future For Anthera's Blisibimod (OTCMKTS:ANTH) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
PNK
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 36.5 (%) |
| Held by Institutions | 48.7 (%) |
| Shares Short | 11 (K) |
| Shares Short P.Month | 10 (K) |
| EPS | 4.65 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -8.57 |
| Profit Margin | 13.8 % |
| Operating Margin | 17.7 % |
| Return on Assets (ttm) | 32.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 10.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 33.58 |
| EBITDA (p.s.) | 8.16 |
| Qtrly Earnings Growth | -19.2 % |
| Operating Cash Flow | 20 (M) |
| Levered Free Cash Flow | 17 (M) |
| PE Ratio | 13.88 |
| PEG Ratio | 0 |
| Price to Book value | -7.54 |
| Price to Sales | 1.92 |
| Price to Cash Flow | 13.1 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|